Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Seattle Genetics doses first patient in Phase I trial of SEA-BCMA

The micrograph shows abundant (malignant) plasma cells with the occasional Mott cell. Credit: Nephron.



  • Seattle Genetics

Go Top